Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis

Journal of Infectious Diseases

Volumn 188, Issue 3, 2003, Pages 458-464

  Murray, Henry W ^a   Moreira, Andre L ^b   Lu, Cristina M ^a   DeVecchio, Jennifer L ^c   Matsuhashi, Maki ^a   Ma, Xiaojing ^a   Heinzel, Frederick P ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR MONOCLONAL ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 12 PROTEIN 40; MONOCLONAL ANTIBODY; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GRANULOMA; IMMUNOTHERAPY; KNOCKOUT MOUSE; LEISHMANIA DONOVANI; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TH1 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; FEMALE; GRANULOMA; INTERFERON TYPE II; INTERLEUKIN-12; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-10;

EID: 0041656392     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/376510     Document Type: Article

References (25)

1. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001; 45:2185-97.
2. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol 1998; 28:669-80.
3. Satoskar AR, Rodig S, Telford SR, et al. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic pathology. Eur J Immunol 2000; 30:834-9.
4. Wilson ME, Sandor M, Blum AM, et al. Local suppression of IFN-γ, in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J Immunol 1996; 156:2231-9.
5. Melby PC, Yang Y-Z, Cheng J, Zhao W. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun 1998; 66:18-27.
6. Taylor A, Murray HW. Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin 12 in experimental visceral leishmanaisis in interferon-γ gene-disrupted mice. J Exp Med 1997; 185:1231-9.
7. Murray HW, Montelibano C, Peterson R, Sypek JP. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J Infect Dis 2000; 182:1497-1502.
8. Murray HW. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol 2001; 82:249-67.
9. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen vs. oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 1999; 189:741-6.
10. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
11. Groux H, Cottrez F, Rouleau M, et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 1999; 162:1723-9.
12. Murphy ML, Wille U, villegas EN, Hunter CA, Farrell JP. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001; 31:2848-56.
13. Murray HW, Lu CM, Mauze S, et al. Interleukin 10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002; 70:6284-93.
14. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD, Murray HW. Induction of Th1- and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 1994; 62:1058-63.
15. Belkaid Y, Hoffmann KF, Mendez S, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194:1497-1506.
16. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166:1141-7.
17. Jones DE, Ackermann MR, Wille U, Hunter CA, Scott P. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect Immun 2002; 70:2151-8.
18. Murray PJ, Wang L, Onufryk C, Tepper RI, Young RA. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol 1997; 158:315-21.
19. Bogdan C, Vodovotz Y, Nathan CF. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174:1549-55.
20. Murray HW, Delph-Etienne S. Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun 2000; 68:288-93.
21. Murray HW, Hariprashad J. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J Exp Med 1995; 181:387-91.
22. Balkhy HH, Heinzel FP. Endotoxin fails to induce interferon-γ in endotoxin tolerant mice: deficiencies in both IL-12 heterodimer production and IL-12 responsiveness. J Immunol 1999; 162:3633-8.
23. Shiloh MU, MacMicking JD, Nicholson S, et al. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 1999; 10:29-38.
24. Nathan CF, Hibbs JB. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 1991; 3:65-70.
25. Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 2000; 68:6289-93.